These findings illustrate the complexity of PD-L1 regulation and suggest that targeting regulatory proteins like DRG2 and CMTM6, in conjunction with immune checkpoint blockade, could effectively combat tumor immune evasion. Here, DRG2 is linked to neoplasm.